Mabworks’ MIL62 Gains NMPA Review for NMOSD Treatment
China-based Beijing Mabworks Biotech Co., Ltd announced that its New Drug Application (NDA) for MIL62,...
Mabworks Biotech
Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development
China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal...
Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange
Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering...
CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890
The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s...
Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...